In a survey conducted among Southeast Asians in November and December 2021, close to 55 percent of respondents chose Pfizer and Moderna as the coronavirus (COVID-19) vaccine manufacturers they trust the most. Approximately 14 percent of respondents stated they trusted any vaccine available.

As of March 9, 2021, there were pre-purchase agreements for over three billion doses of AstraZeneca/Oxford's vaccine. This vaccine is by far the most sought after COVID-19 vaccine, especially due to its ability to be stored at normal refrigerator temperatures, while other vaccines might need ultra cold storage. Although still in phase III of clinical trials and without approval, Novavax's vaccine is the one with the second highest number of orders worldwide.

Global COVID-19 vaccine contracts At the same time, India had managed to secure around 2.2 billion COVID-19 vaccines doses, followed by the European Union which had signed pre-purchase agreements to secure nearly 1.84 billion doses of COVID-19 vaccines, while the United States already secured around 1.21 billion doses. AstraZeneca/Oxford's vaccine accounted for one billion doses of all vaccines secured by India, while also accounting for 300 million doses of all vaccines secured by the EU and the U.S., respectively.

Forecasted sales of COVID-19 vaccines As of November 2021, Comirnaty by BioNTech/Pfizer was the leading COVID-19 vaccine by forecasted sales revenue. It was expected to make around 36 billion U.S. dollars in sales revenue in 2021, followed by 29 billion dollars in 2022. Meanwhile, Spikevax by Moderna was projected to make 18 billion and 22 billion U.S. dollars in 2021 and 2022, respectively. Vaxzevria by AstraZeneca was forecasted to make 1.7 billion U.S. dollars in sales, followed by an additional 1.9 billion dollars by 2022. In contrast to most other biopharmaceutical companies, AstraZeneca had announced to sell its vaccine at almost net cost price.

CDC COVID-19 Vaccine Tracker

Cumulative and Daily Counts of COVID-19 Vaccine Doses in the United States

By Nicky Forster [source]

About this dataset

The dataset contains data points such as the cumulative count of people who have received at least one dose of the vaccine, new doses administered on a specific date, cumulative count of doses distributed in the country, percentage of population that has completed the full vaccine series, cumulative count of Pfizer and Moderna vaccine doses administered in each state, seven-day rolling averages for new doses administered and distributed, among others.

It also provides insights into the vaccination status at both national and state levels. The dataset includes information on the percentage of population that has received at least one dose of the vaccine, percentage of population that has completed the full vaccine series, cumulative counts per 100k population for both distributed and administered doses.

Additionally, it presents data specific to each state, including their abbreviation and name. It outlines details such as cumulative counts per 100k population for both distributed and administered doses in each state. Furthermore, it indicates if there were instances where corrections resulted in single-day negative counts.

The dataset is compiled from daily snapshots obtained from CDC's COVID Data Tracker. Please note that there may be reporting delays by healthcare providers up to 72 hours after administering a dose.

This comprehensive dataset serves various purposes including tracking vaccination progress over time across different locations within the United States. It can be used by researchers, policymakers or anyone interested in analyzing trends related to COVID-19 vaccination efforts at both national and state levels

How to use the dataset

• Familiarize Yourself with the Columns: Take a look at the available columns in this dataset to understand what information is included. These columns provide details such as state abbreviations, state names, dates of data snapshots, cumulative counts of doses distributed and administered, people who have received at least one dose or completed the vaccine series, percentages of population coverage, manufacturer-specific data, and seven-day rolling averages.

• Explore Cumulative Counts: The dataset includes cumulative counts that show the total number of doses distributed or administered over time. You can analyze these numbers to track trends in vaccination progress in different states or regions.

• Analyze Daily Counts: The dataset also provides daily counts of new vaccine doses distributed and administered on specific dates. By examining these numbers, you can gain insights into vaccination rates on a day-to-day basis.

• Study Population Coverage Metrics: Metrics such as pct_population_received_at_least_one_dose and pct_population_series_complete give you an understanding of how much of each state's population has received at least one dose or completed their vaccine series respectively.

• Utilize Manufacturer Data: The columns related to Pfizer and Moderna provide information about the number of doses administered for each manufacturer separately. By analyzing this data, you can compare vaccination rates between different vaccines.

• Consider Rolling Averages: The seven-day rolling average columns allow you to smooth out fluctuations in daily counts by calculating an average over a week's time window. This can help identify long-term trends more accurately.

• Compare States: You can compare vaccination progress between different states by filtering the dataset based on state names or abbreviations. This way, you can observe variations in distribution and administration rates among different regions.

• Visualize the Data: Creating charts and graphs will help you visualize the data more effectively. Plotting trends over time or comparing different metrics for various states can provide powerful visual representations of vaccination progress.

• Stay Informed: Keep in mind that this dataset is continuously updated as new data becomes available. Make sure to check for any updates or refreshed datasets to obtain the most recent information on COVID-19 vaccine distributions and administrations

Research Ideas

• Vaccination Analysis: This dataset can be used to analyze the progress of COVID-19 vaccinations in the United States. By examining the cumulative counts of doses distributed and administered, as well as the number of people who have received at least one dose or completed the vaccine series, researchers and policymakers can assess how effectively vaccines are being rolled out and monitor...

New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.

https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html

Pfizer Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Initial-Allocations-Pfizer/saz5-9hgg

Moderna Vaccine Data- https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/b7pe-5nws

As of April 26, 2023, roughly 367 million Pfizer-BioNTech COVID-19 vaccine doses had been administered in the United States. This statistic shows the number of COVID-19 vaccinations administered in the United States as of April 26, 2023, by manufacturer.

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in va

ObjectivesTo characterize factors associated with parental willingness for their children participation in a COVID-19 vaccine trial, use of different COVID-19 vaccines and acceptance of a third vaccine dose.MethodsParents of children aged 12–17 years in Lima, Perú were asked to complete an online questionnaire via social networks, from November 9, 2021, to April 23, 2022. We calculated crude and adjusted prevalence ratios with 95% confidence intervals to compare factors with the mentioned outcomes.ResultsFrom 523 parents responding, 374 completed the survey. 90.4% would give their children a third vaccine dose, 36.6% would allow their children participation in a COVID-19 vaccine clinical trial, and 33.2% would accept different vaccine brands between doses. Parental belief that COVID-19 vaccine studies met quality standards was associated with acceptance of a third booster dose (adjusted PR 3.25; 95% CI1.57–6.74; p = 0.002), enrolment in a COVID-19 clinical trial (adjusted PR 4.49; 95% CI1.25–16.06; p = 0.02), and acceptance of different COVID-19 vaccine brands between doses (adjusted PR 10.02; 95% CI1.40–71.95; p = 0.02).ConclusionMost parents would accept a third vaccine booster dose, approximately a third would participate in COVID-19 vaccine trials. Believing COVID-19 vaccines studies fulfilled quality standards was associated with the study outcomes. It is necessary to inform about the rigorous processes for the development of COVID-19 vaccines to generate confidence in parents to accept these vaccine-related outcomes.

NOTE: As of 2/16/2023, this page is not being updated. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated and had additional dose 1 grouped by whether they live in an SVI Priority Zip Code. People with an out-of-state zip code are excluded from this analysis. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. A person who has received at least one dose of any COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary vaccine series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional dose of COVID-19 vaccine is considered to have had additional dose 1. The additional monovalent dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. SVI refers to the CDC's Social Vulnerability Index - a measure that combines 15 demographic variables to identify communities most vulnerable to negative health impacts from disasters and public health crises. Measures of social vulnerability include socioeconomic status, household composition, disability, race, ethnicity, language, and transportation limitations - among others. SVI scores were calculated for each zip code in CT. The zip codes in the top 20% were designated as SVI Priority Zip Codes. Percentages are based on 2018 zip code population data supplied by ESRI corporation. The percent with at least one dose many be over-estimated and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ.  Data reported here reflect the vaccination records currently reported to CT WiZ. Note: As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021.

ObjectiveThis study aimed to map the existing literature to identify predictors of COVID-19 vaccine acceptability among refugees, immigrants, and other migrant populations.MethodsA systematic search of Medline, Embase, Scopus, APA PsycInfo and Cumulative Index of Nursing and Allied Health Literature (CINAHL) was conducted up to 31 January 2023 to identify the relevant English peer-reviewed observational studies. Two independent reviewers screened abstracts, selected studies, and extracted data.ResultsWe identified 34 cross-sectional studies, primarily conducted in high income countries (76%). Lower vaccine acceptance was associated with mistrust in the host countries’ government and healthcare system, concerns about the safety and effectiveness of COVID-19 vaccines, limited knowledge of COVID-19 infection and vaccines, lower COVID-19 risk perception, and lower integration level in the host country. Female gender, younger age, lower education level, and being single were associated with lower vaccine acceptance in most studies. Additionally, sources of information about COVID-19 and vaccines and previous history of COVID-19 infection, also influence vaccine acceptance. Vaccine acceptability towards COVID-19 booster doses and various vaccine brands were not adequately studied.ConclusionsVaccine hesitancy and a lack of trust in COVID-19 vaccines have become significant public health concerns within migrant populations. These findings may help in providing information for current and future vaccine outreach strategies among migrant populations.

Unlike many other industrial societies, the partisan fights on the vaccination against COVID-19 in Taiwan centered on its brand choice rather than acceptance. Did the incumbent DPP supporters adhere to their party line of Medigen to vaccinate against COVID-19 during the pandemic? We argue that individual COVID-19 vaccine brand choices as gradually updated judgements during the pandemic were not solely determined by the party line, but jointly shaped by the strength of party affiliation and the level of government trust to facilitate decision making in the highly uncertain information environment at the early stage of the pandemic. More specifically, when choosing COVID-19 vaccine brand, the incumbent DPP supporters, particularly weak ones, were more likely to adhere to their party line of Medigen as they trusted government more; however, this was only for the highly uncertain first shot, due to the absence of reliable information for making informed judgements about COVID vaccine brand choice at the early stage of the pandemic, not for the informationally rich booster shot. We report empirical findings consistent with our argument from statistical analyses of original data from a survey of 1642 Taiwanese adult respondents conducted in the fall of 2022.

NOTE: As of 2/16/2023, this table is no longer being updated. For data on COVID-19 Updated (Bivalent) Booster Coverage by Age go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Age-/j2me-7k56. For information on COVID-19 vaccination primary series coverage for people less than 5 years go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccination-Primary-Series-Coverage-Age-L/su9q-qn6e

Important change as of June 1, 2022

As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages for state- and county-level tables (except coverage by CT SVI priority zip code). 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator.

• DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated, and addition dose 1 by age group. Age is based on age at the time of administration of the first dose.

All data in this report are preliminary; data for previous dates will be updated as new reports are received, and data errors are corrected.

Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used.

In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations.

The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated when records for an individual cannot be linked because of differences in how names or date of birth are reported.

Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. This includes doses given to residents of CT and to residents of other states vaccinated in CT. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records reported to CT WiZ. However, once CT residents who have received doses in each jurisdiction are added to CT WiZ, the records for residents of that jurisdiction vaccinated in CT are removed. For example, when CT residents vaccinated in NYC were added, NYC residents vaccinated in CT were removed.

Note: As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021.

The inhaled COVID-19 vaccine market is poised for significant growth, driven by the inherent advantages of this delivery method. Unlike traditional intramuscular injections, inhaled vaccines offer several key benefits, including improved mucosal immunity, potentially leading to broader and longer-lasting protection against infection and transmission. This is particularly crucial given the evolving nature of the virus and the emergence of new variants. Furthermore, the ease of administration and reduced reliance on trained healthcare professionals make inhaled vaccines a compelling alternative, especially in resource-constrained settings or mass vaccination campaigns. While the market is currently nascent, the potential for rapid expansion is substantial, fueled by ongoing research and development efforts focusing on efficacy, safety, and scalability. Factors such as regulatory approvals, public acceptance, and the continuous threat of future pandemics will significantly influence market trajectory. We estimate the market size in 2025 to be approximately $500 million, with a Compound Annual Growth Rate (CAGR) of 25% from 2025-2033, projecting a market value exceeding $3 billion by 2033. This growth is contingent upon successful clinical trials and widespread adoption by health organizations globally.
Several factors are expected to influence the market. Government support for vaccine development and distribution will play a pivotal role. Furthermore, the emergence of new viral variants and the potential need for annual booster shots will further stimulate demand. However, challenges remain. These include overcoming potential production bottlenecks, ensuring equitable access to vaccines in both developed and developing countries, and addressing any safety concerns through comprehensive clinical trials and data transparency. Companies such as CanSino Biologics are leading the way in developing inhaled COVID-19 vaccines, and their progress will be crucial to shaping the market's future landscape. The competitive landscape will likely intensify as other pharmaceutical companies enter the field.

Data on persons vaccinated for COVID-19 by vaccine brand, province and date of vaccination. Campaign 24/25

NOTE: As of 2/16/2023 this table is no longer being updated. For information on COVID-19 Updated (Bivalent) Booster Coverage, go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Race/8267-bg4w.

Important change as of June 1, 2022

As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages by age at the state level. 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator.

• DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

This table shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated and had additional dose 1 by race / ethnicity and age group.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator.

Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used.

In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations.

The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Race and ethnicity data may be self-reported or taken from an existing electronic health care record. Reported race and ethnicity information is used to create a single race/ethnicity variable. People with Hispanic ethnicity are classified as Hispanic regardless of reported race. People with a missing ethnicity are classified as non-Hispanic. People with more than one race are classified as multiple races.

A vaccine coverage percentage cannot be calculated for people classified as NH Other race or NH Unknown race since there are not population size estimates for these groups. Data quality assurance activities suggest that in at least some cases NH Other may represent a missing value. Vaccine coverage estimates in specific race/ethnicity groups may be underestimated as result of the classification of records as NH Unknown Race or NH Other Race.

Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. This includes doses given to residents of CT and to residents of other states vaccinated in CT. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records reported to CT WiZ. However, once CT residents who have received doses in each jurisdiction are added to CT WiZ, the records for residents of that jurisdiction vaccinated in CT are removed. For example, when CT residents vaccinated in NYC were added, NYC residents vaccinated in CT were removed.

Note: This dataset takes the place of the original "COVID-19 Vaccinations by Race/Ethnicity" dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Race-Ethnicity/xkga-ifz3 ), which will not be updated after 5/20/2021 and “COVID-19 Vaccinations by Race / Ethnicity” dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Race-Ethnicity/ybkg-w5x2), which will not be updated after 10/20/2021.

The COVID-19 vaccine market, while experiencing a significant surge during the initial pandemic years, is now facing a period of contraction. The market's rapid expansion was driven by urgent global health needs, mass vaccination campaigns, and substantial government investment. However, the deceleration of the CAGR to -37.4% reflects a shift towards a more stable, albeit smaller, market. This downturn is attributable to several factors. Firstly, a large portion of the global population has already received primary vaccination courses, reducing immediate demand. Secondly, the emergence of new variants and the waning efficacy of initial vaccines have led to booster campaigns, but these are less extensive than the initial rollout. Furthermore, ongoing efforts towards developing next-generation vaccines, including those targeting newer variants or offering broader protection, are influencing the market landscape. The market segmentation by type (mRNA, viral vector, etc.) and application (primary vaccination, booster doses) will continue to be crucial factors influencing the market's evolution, with ongoing research and development likely driving future growth in specific segments. The competitive landscape remains highly consolidated with major players like Pfizer, Moderna, Johnson & Johnson, and others holding significant market share. These companies are actively engaged in expanding their vaccine portfolios, securing supply agreements, and exploring new market opportunities, particularly in emerging economies and for long-term vaccination programs. The geographical distribution of the market remains regionally diverse. North America and Europe, with their advanced healthcare systems and early adoption of vaccines, historically held the largest market shares. However, as vaccination programs progress in other regions, we can expect a gradual shift in market share distribution towards Asia Pacific and other developing regions as these areas increase vaccination rates and investment in related healthcare infrastructure. The long-term market will be driven by factors such as the emergence of new variants, the development of updated vaccines, the need for booster shots, and the potential for seasonal COVID-19 vaccination programs. Continued government support and private investment will be crucial for ensuring the long-term viability and sustainability of the COVID-19 vaccine market. Given the potential for future pandemics, the market is likely to remain relevant though significantly reduced compared to its peak during the initial pandemic phases.

As of July 21, 2022, most countries in the European Economic Area (EEA) had received the majority of their COVID-19 vaccine stock from Comirnaty (Pfizer/BioNTech). In Denmark, the Comirnaty vaccine accounted for 83 percent of the total COVID-19 vaccines distributed to the country. Hungary was the first country in the EEA to have received COVID-19 vaccines from Sinopharm and Sputnik V which were developed in China and Russia respectively. The current rate of COVID-19 vaccines administered in Europe can be found here. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

The global oral COVID-19 vaccine market is projected to reach $1224.9 million in 2025 and is poised for substantial growth, exhibiting a Compound Annual Growth Rate (CAGR) of 5% from 2025 to 2033. This expansion is driven by several key factors. The increasing demand for convenient and needle-free vaccination options, particularly among populations hesitant about injections, is a significant catalyst. Furthermore, the potential for improved accessibility and affordability compared to traditional injectable vaccines, especially in low- and middle-income countries with limited healthcare infrastructure, contributes to market growth. Ongoing research and development efforts focused on enhancing efficacy and addressing potential side effects further fuel market expansion. The market segmentation reveals strong demand across diverse age groups (adults, children, and the elderly), with varying formulations (tablet and inhalable types) catering to specific needs and preferences. Leading pharmaceutical companies are actively investing in oral vaccine development and production, indicating a robust and competitive landscape. The market's growth is not without its challenges. Regulatory hurdles and stringent approval processes can impact the timely market entry of new oral vaccines. Concerns regarding the efficacy and duration of immunity conferred by oral vaccines compared to injectable counterparts pose another challenge. Furthermore, the evolving nature of the virus itself necessitates continuous adaptation and innovation in oral vaccine development to maintain effectiveness against new variants. Nevertheless, the convenience and accessibility offered by oral COVID-19 vaccines, coupled with the ongoing research and development efforts, are expected to propel market growth, with significant opportunities for established pharmaceutical players and emerging biotech companies alike. The regional distribution is expected to be heavily influenced by healthcare infrastructure and population density, with North America and Europe leading initially, followed by Asia Pacific as production and distribution networks expand.

Approved COVID-19 Vaccines Market Outlook

The global market size for approved COVID-19 vaccines was estimated at $43.1 billion in 2023 and is projected to reach $82.2 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period. This remarkable growth is primarily driven by the ongoing efforts to control the pandemic, increasing vaccination rates, and the development of enhanced vaccine formulations. The demand for booster doses and the inclusion of younger age groups in vaccination programs also contribute significantly to the market's expansion.

One of the primary growth factors in the approved COVID-19 vaccines market is the continuous innovation and development of vaccines to address emerging variants of the virus. Companies are investing heavily in research and development to create vaccines that offer broader protection and longer-lasting immunity. The rapid approval processes implemented by regulatory bodies worldwide have also facilitated the timely introduction of new vaccines, thereby accelerating market growth. Additionally, pharmaceutical companies are leveraging advanced technologies such as mRNA to develop highly effective and adaptable vaccines.

Another significant growth factor is the global vaccination campaigns launched by governments and health organizations. These campaigns aim to achieve herd immunity and curb the spread of COVID-19, resulting in a high volume of vaccine administration. International collaborations and funding initiatives have also played a crucial role in ensuring the availability and accessibility of vaccines, especially in low- and middle-income countries. Furthermore, public awareness about the importance of vaccination in preventing severe illness and death has led to increased acceptance and uptake of COVID-19 vaccines.

The expansion of vaccination programs to include booster doses and vaccinations for children and adolescents has also fueled market growth. As new COVID-19 variants emerge, booster doses are becoming necessary to maintain adequate immunity levels in the population. Pediatric vaccinations are gaining approval and are being integrated into national immunization schedules, further driving the demand for COVID-19 vaccines. Moreover, the development of combination vaccines that protect against multiple viruses, including COVID-19, is anticipated to boost market growth in the coming years.

From a regional perspective, North America and Europe are currently the leading markets for approved COVID-19 vaccines, owing to their well-established healthcare infrastructure, high vaccination rates, and substantial government funding for vaccine procurement and distribution. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period, driven by large population bases, increasing public and private investments in healthcare, and robust vaccination campaigns. Latin America, the Middle East, and Africa are also anticipated to contribute to market growth, although at a comparatively slower pace.

The role of packaging in the distribution of COVID-19 vaccines cannot be overstated, with the COVID-19 Vaccine Bottle being a critical component in ensuring the safe and effective delivery of vaccines worldwide. These bottles are designed to maintain the stability and efficacy of the vaccine by protecting it from environmental factors such as temperature fluctuations and contamination. The development and production of vaccine bottles have seen significant advancements, with manufacturers focusing on materials that offer enhanced durability and safety. Moreover, the standardization of bottle sizes and labeling has facilitated streamlined logistics and distribution processes, ensuring that vaccines reach their intended destinations efficiently. As the demand for COVID-19 vaccines continues to grow, the production and innovation in vaccine bottles are expected to play a pivotal role in supporting global vaccination efforts.

Vaccine Type Analysis

The market for approved COVID-19 vaccines can be segmented by vaccine type, with mRNA vaccines, vector vaccines, protein subunit vaccines, inactivated vaccines, and others constituting the primary categories. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, have gained significant attention due to their high efficacy rates and rapid

NOTE: As of 2/16/2023, this page is not being updated. For data on updated (bivalent) COVID-19 booster vaccination click here: https://app.powerbigov.us/view?r=eyJrIjoiODNhYzVkNGYtMzZkMy00YzA3LWJhYzUtYTVkOWFlZjllYTVjIiwidCI6IjExOGI3Y2ZhLWEzZGQtNDhiOS1iMDI2LTMxZmY2OWJiNzM4YiJ9 This table shows the number and percent of people that have initiated COVID-19 vaccination and are fully vaccinated by CT census tract (including residents of all ages). It also shows the number of people who have not received vaccine and who are not yet fully vaccinated. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. A person who has received at least one dose of any vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. The percent with at least one dose many be over-estimated and the percent fully vaccinated may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Population data obtained from the 2019 Census ACS (www.census.gov) Geocoding is used to determine the census tract in which a person lives. People for who a census tract cannot be determined based on available address data are not included in this table. DPH recommends that these data are primarily used to identify areas that require additional attention rather than to establish and track the exact level of vaccine coverage. Census tract coverage estimates can play an important role in planning and evaluating vaccination strategies. However, inaccuracies in the data that are inherent to population surveillance may be magnified when analyses are performed down to the census tract level. We make every effort to provide accurate data, but inaccuracies may result from things like incomplete or inaccurate addresses, duplicate records, and sampling error in the American Community Survey that is used to estimate census tract population size and composition. These things may result in overestimates or underestimates of vaccine coverage. Some census tracts are suppressed. This is done if the number of people vaccinated is less than 5 or if the census population estimate is considered unreliable (coefficient of variance > 30%). Coverage estimates over 100% are shown as 100%. Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records currently reported to CT WiZ. Caution should be used when interpreting coverage estimates in towns with large college/university populations since coverage may be underestimated. In the census, college/university students who live on or just off campus would be counted in the college/university town. However, if a student was vaccinated while studying remotely in his/her hometown, the student may be counted as a vaccine recipient in that town. As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021. As of 1/13/2021, census tract level data are provider by town for all ages. Data by age group is no longer available.

NOTE: As of 2/16/2023, this table is not being updated. For data on COVID-19 updated (bivalent) booster coverage by town please to go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Town/bqd5-4jgh. This table shows the number and percent of residents of each CT town that have initiated COVID-19 vaccination, are fully vaccinated and who have received additional dose 1 by age group. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Town of residence is verified by geocoding the reported address and then mapping it a town using municipal boundaries. If an address cannot be geocoded, the reported town is used. Out-of-state residents vaccinated by CT providers are excluded from the table. The population denominators for these town- and age-specific coverage estimates are based on 2014 census estimates. This is the most recent year for which reliable town- and age-specific estimates are available. (https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Town-Population-with-Demographics). This census data is grouped in 5-year age bands. For vaccine coverage age groupings not consistent with a standard 5-year age band, each age was assumed to be 20% of the total within a 5-year age band. However, given the large deviation from this assumption for Mansfield because of the presence of the University of Connecticut, the age distribution observed in the 2010 census for the age bands 15 to 19 and 20 to 24 was used to estimate the population denominators. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Caution should be used when interpreting coverage estimates for towns with large college/university populations since coverage may be underestimated. In the census, college/university students who live on or just off campus would be counted in the college/university town. However, if a student was vaccinated while studying remotely in his/her hometown, the student may be counted as a vaccine recipient in that town. Connecticut COVID-19 Vaccine Program p